LRBA: A Sensitive Biomarker and Effective Therapeutic Target for Inflammatory Diseases
- Technology Benefits
- Noninvasive biomarkerSafe and efficient therapyCardiovascular relevance
- Technology Application
- pro-inflammatory marker and therapeutic strategy
- Detailed Technology Description
- Our inventors have determined that LRBA is a master regulator for many important genes involved in immune disorder such as autoimmunity, immunodeficiency and other inflammatory diseases. Since LRBA levels in healthy controls and patients with controlled symptoms are virtually undetectable, LRBA serves as a convenient noninvasive biomarker. LRBA also possibly could be used as a therapeutic target through giving intravenous injections to replenish LRBA in patients who lack functional LRBA. Conversely, in the event of LRBA over-expression, which may cause inflammation, LRBA antibodies or LRBA dominant negative mutants (DNM) possibly could be used to block LRBA function to treat inflammatory diseases such as cardiovascular disease, a complex chronic inflammatory disease, since LRBA is highly expressed in the heart.
- *Abstract
-
The University of South Florida has developed a sensitive biomarker and effective therapeutic target for inflammatory diseases using lipopolysaccharide (LPS)-responsive beige-like anchor (LRBA). This protein can serve as a convenient noninvasive tool for diagnosis, prognosis and treatment of inflammatory diseases such as asthma exacerbation, rheumatoid arthritis, ulcerative colitis and sepsis.
- Country/Region
- USA
For more information, please click Here
